Christophe Massard

Implementation of a Clinical Decision Support System for Precision Oncology across an Academic Network

David Tamborero, Carlos Caldas, Giovanni Apolone, 2021 .

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial

Marie-Cécile Le Deley, Charles Ferté, Philippe Vielh, 2016, Clinical Cancer Research.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Charles Ferté, Laurent Dercle, Samy Ammari, 2016, Clinical Cancer Research.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Marie-Cécile Le Deley, Stefan Michiels, Caroline Even, 2017, Cancer discovery.

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Percy Ivy, Xavier Paoletti, Laurence Collette, 2014, European journal of cancer.

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

Andrew Kramar, Caroline Bascoul-Mollevi, Christophe Massard, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carcinomas of an unknown primary origin—diagnosis and treatment

Christophe Massard, Y. Loriot, K. Fizazi, 2011, Nature Reviews Clinical Oncology.

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Christophe Massard, M. Gross, S. Culine, 2009, Clinical Cancer Research.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Nicholas J. Vogelzang, Jingsong Zhang, Michael Ong, 2017, JAMA oncology.

Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib

Linda Chami, Nathalie Lassau, Serge Koscielny, 2012, Investigational New Drugs.

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence

Charles Ferté, Mathilde Bateson, Eric Deutsch, 2017, Scientific Reports.